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Background: Cardiac complications are among the most serious problems of thalassemia intermedia patients. The
current study was initiated to address the latter issue through the study of the echocardiographic findings and
correlate it with clinical characteristics of thalassemia intermedia patients in Duhok, Kurdistan region, Iraq.
Methods: An echocardiographic assessment of 61beta-thalassemia intermedia cases was performed. It included
30 males and 31 females, with a mean age 19.6 ± 7.5 years. The standard echostudy of two-dimension and M-mode
measurements of cardiac chambers were done. The continuous doppler regurgitant jet of tricuspid and pulmonary
valves were recorded. Left ventricle diastolic function was assessed by pulsed doppler of mitral valve inflow. To
correlate the clinical with echocardiographic findings, patients were divided, according to tricuspid regurgitant
velocity, into three groups (<2.5 m/sec, 2.5-2.9 m/sec and ≥3 m/sec).
Results: Tricuspid regurgitant velocity <2.5 m/sec, 2.5-2.9 m/sec and ≥3 m/sec occurred in 42(69%), 11(18%) and
8(13%) respectively. Comparing to other groups patients with tricuspid regurgitant velocity ≥3 m/sec were older
and included more males. They had lower hemoglobin levels, but higher ferritin levels. Their age at diagnosis and
the age of the initiation of blood transfusion were later. Most of them had significant exertional dyspnea. They also
had relatively lower left ventricle ejection fraction values. Right ventricular diameter and right atrial size were larger
in the same group. Tricuspid regurgitant velocity as a continuous predictor was associated positively with age,
cardiac volumes and pulmonary regurgitation though negatively associated with ejection fraction.
Conclusions: Echo-derived right and left side cardiac complications are not uncommon in thalassemia intermedia
patients. Therapeutic trails targeting these complications are indicated, and echocardiographic assessment is
necessary to be offered early for thalassemia intermedia.
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Thalassemia Intermedia (TI) is an inherited hemoglobin
disorder that is characterized by a significant genetic and
clinical heterogeneity.
Cardiovascular involvement represents a well-known
complication and the primary cause of mortality in TI.
It is mainly determined by the fact that both ventricles
have to maintain a high cardiac output level through a
stiff vascular bed. Pulmonary hypertension and steady
increase in tricuspid regurgitant jet followed by right
heart failure dominates the clinical picture.Correspondence: doctoramb@yahoo.com
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unless otherwise stated.The left ventricle has to maintain a high cardiac out-
put in a continuous state of both volume and pressure
overload which consequently contributes to left ven-
tricular impairment with time [1-3].
Several factors have been reported to interfere in the
pathophysiology of cardiovascular abnormalities in TI.
However, the key mechanism is the chronic tissue hyp-
oxia and chronic hemolysis with its consequences [3].
The screening of patients with thalassemia intermedia
for evidence of cardiac complications by transthoracic
echostudy is a good option for early diagnosis and even-
tually for future planning of best management of cardiac
complications. The purpose of this study is to look for
evidence of cardiac involvement by echocardiographyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ical characteristics of patients with TI.
Methods
This is a prospective study of 61 beta-thalassemia inter-
media patients (out of total 74 registered in Duhok thal-
assemia center). It included 30 males and 31 females,
with a mean age of 19.6(SD7.5) years. All patients were
evaluated by history taking and physical examination, la-
boratory studies, and underwent transthoracic echocar-
diography between June 2010 and June 2011. Either
patients or their relatives provided written informed
consent.
Transthoracic echocardiography was performed for all
patients by Vivid 3(GE) Echo systems. The standard
two-dimension and M-mode measurements of the car-
diac chambers including left ventricle ejection fraction
(LVEF %) were taken. Cardiac volumes and dimensions
were indexed by body surface area. Tricuspid regurgita-
tion was assessed in the apical four chambers, paraster-
nal short axis views, and a minimum of three sequential
complexes were recorded. Continuous doppler sampling
of the peak regurgitant jet to estimate the right ventri-
cular to right atrial systolic pressure gradient by the
modified Bernoulli equation was obtained. To assess the
mean pulmonary artery pressure, the pulmonary artery
to right ventricular pressure gradient was estimated from
the peak pulmonary regurgitant flow velocity (V) in
parasternal short axis view by the simplified Bernoulli
equation (PG = 4 V2) [4]. Left ventricle diastolic function
was assessed by pulsed doppler sampling of mitral valve
inflow in four apical chambers view. The peak E and A
waves velocities and the E/A ratio of the mitral valve
were recorded. All echocardiographic measurements
were performed according to American society of echo-
cardiography recommendations [5].
To correlate between the clinical and Echo findings
within the studied sample, the patients were divided ac-
cording to tricuspid regurgitant velocity (TRV) into three
groups (TRV < 2.5 m/sec, 2.5-2.9 m/sec and ≥3 m/sec) [6].
Additionally, TRV was taken as a continuous variable to
assess its associations with clinical and echocardiographic
findings. Data of blood transfusion history were catego-
rized into: regularly transfused (patients transfused at
regular intervals every 1–3 months for last year prior to
study enrollment) and irregularly transfused (≤ 3 units of
blood/ year). Continuous variables were calculated as
mean (SD) and categorical variables were presented as
counts and percentages. ANOVA and a Fisher’s exact tests
were used for the comparison of continuous and categor-
ical variables respectively. Scatter plots with line regression
were used for the analysis of TRV as a continuous variable
with other predictors. P-value < 0.05 was considered sig-
nificant. The study was approved by the ethical committeeat the School of Medicine, Faculty of Medical Sciences,
University of Duhok.
Results
Correlations of clinical characteristics to TRV
Since patients have been classified into three groups
according to the TRV, 42(69%) had TRV <2.5 m/sec,
8(13%) had ≥ 3 m/sec, the remaining 11(18%) had be-
tween these two values. Patients with highest TRV were
older. Almost all of them were over 12 years old. Their
age at diagnosis and first blood transfusion were later.
Majority of them were male with significant exertional
dyspnea. Their Hemoglobin level was lower, but ferritin
was higher. Most of them were splenectomized. BSA
was higher in the same group as shown in Table 1.
Echocardiographic findings in relation to TRV
Higher TRV values were significantly associated with in-
creased cardiac chamber indices. These indices included
left ventricle end diastolic diameter (LVEDD), left ventricle
end systolic diameter (LVESD), left atrial (LA) diameter,
and right ventricle (RV) diameter and right atrial (RA)
size. There was a relatively slight decrease in the ejection
fraction at the highest levels of jet velocity. There was an
increase in the mean of LV wall and septal thickness with
higher TRV values, though it did not reach the significant
difference. The peak gradients of tricuspid and pulmonary
valves were significantly associated with an increasing
degree of TRV as shown in Table 2.
Associations of TRV as a continuous variable with other
predictors
Scatter plots of TRV with age and echocardiographic
predictors showed a significant association with age,
LVEDD, LVESD, LA diameter, RV diameter, RA area and
PR peak gradient. But there was a negative association
with LVEF % as shown in Figures 1, 2, 3, 4, 5, 6, 7 and 8.
Discussion
The main findings of the study are the following: first,
both the left and right cardiac chambers, especially the
dimensions and volumes, were increased in TI patients
with time. Second, patients with higher TRV were pre-
sented with advancing age, later age at diagnosis, later
onset of initiation of blood transfusion, predominant
male gender, lower hemoglobin level, higher ferritin
rates, and higher percentage of splenectomised patients.
Third, the LVEF % was normal. It was relatively lower
for the patients with higher TRV. Three patients had
features of congestive heart failure.
Some of TI patients have an exceptional hemodynamic
pattern consistent with right ventricular cardiomyopathy
and PHT as well as the left ventricular abnormalities that
can be a leading cause of cardiopulmonary problems in
Table 1 Clinical characteristics of TI patients in relation to TR jet velocity
Characteristics Jet velocity <2.5 m/sec 42(69%) Jet velocity 2.5-2.9 m/sec 11(18%) Jet velocity ≥ 3.0 m/sec 8(13%) p-value
Mean Age(year) 14.0(SD11.2) 19.0(SD 5.0) 26(SD 6.30) 0.007
Age≥ 12 Years 19(45.23%) 8(72.72%) 8(100%) 0.004
Age at Diagnosis(year) 6.40(SD1.74) 8.02(SD1.06) 9.10(SD1.2 0) <0.001
Sex(male) 16(38%) 8(72%) 6(75%) 0.01
BSA(m2) 0.98(SD0.37) 1.40(SD0.25) 1.46(SD0.13) <0.001
BMI(kg/m2) 16.95(SD2.91) 18.09(SD2.15) 19.47(SD2.54) 0.05
Exertional dyspnea 4(9.5%) 3(27%) 6(75%) <0.001
Hemoglobin level(g/dl) 9.10(SD1.2) 8.02(SD1.0) 7.90(SD1.10) 0.003
Ferritin level(ng/ml) 987.5(SD545) 932(SD674) 1650(SD824) 0.01
Age of 1st BT^ 7.50(SD5.70) 10.80(SD6.70) 13.7(SD6.20) 0.01
Regular BT^ 11(23.8%) 2(9%) 2(12.5%) 0.8
Splenectomized 6(14%) 2(18%) 5(62%) 0.01
^BT = Blood transfusion. Data are presented as count (%) or mean ± SD.
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in patients may indicate that those at risk of developing
symptomatic cardiac disease. These patients might then
become candidates for more intensive therapy including
blood transfusion and sustained iron chelation [7,8].
The present study showed that the left ventricular di-
mensions including (LVEDD and LVESD) in TI were in-
creased with an increase in the TRV. This is in consistence
with previous studies by Nouri et al., Aessopos et al. and
Vaccari et al. [9,2,10]. The mean of LV septal and posterior
wall dimensions during systole and diastole were increased
in spite of statistical insignificance. This finding is consist-
ent with those of Aessopos et al. and Nurri et al. studiesTable 2 Echo findings of TI patients according to TR jet veloc







LVEF (%) 65(SD6.40) 64(SD7.20)




RV diameter (cm/m2) 1.24(SD0.62) 1.57(SD0.7
RA area(cm2/m2) 9.11(SD4.20) 12.6(SD3.1
TAPSE(cm) 2.66(SD1.02) 2.33(SD0.9
TR peak gradient (mmHg) 21.55(SD10.23) 27.21(SD7.
PR peak gradient (mmHg) 10.20(SD4.10) 13.25(SD6.
EF: Ejection fraction, IVSDD: Interventricular septum diastolic diameter, LVEDD: Left
diameter, IVSSD: Interventricular septum systolic diameter, LVESD: Left ventricle end
Left atrium, RV: Right ventricle, RA: Right atrium, TAPSE: Tricuspid annular plane sys[2,9]. The larger LV dimensions could be explained by the
presence of chronic anemia, which is associated with in-
creased blood volume. The lower capacity of blood to
carry an adequate amount of oxygen to peripheral tissues
was overcome by higher cardiac output and the venous
return was, therefore; increased. This significant volume
overload was carried out through the Frank-Starling
mechanism [10].
Evaluating LV systolic function, the mean LVEF % in
the studied sample was normal. There was a negative
association between TRV and LVEF % with correlation
coefficient equal to (−0.39). However, comparing LVEF %
among subgroups, there was a significant differenceity















ventricle end diastolic diameter, LVPWDD: Left ventricle posterior wall diastolic
systolic diameter, LVPWSD: Left ventricle posterior wall systolic diameter, LA:
tolic excursion, TR: Tricuspid regurgitation, PR: Pulmonary regurgitation.
Figure 1 Association of TRV with age of patients.
Figure 3 Association of TRV with LVESD.
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est TRV sample that included three patients with fea-
tures of congestive heart failure. According to Aessopos
et al. [3] the LVEF % was normal in TI. However it was
lower than LVEF % of control group with a significant
difference (p < 0.05) [3]. Noori et al. [11] found signifi-
cant lower values of LVEF % among TI compared to
control group (p = 0.001). Vaccari et al. study showed
lower LVEF % among TI though insignificant compared
to control group [10]. Tissue doppler, a recently intro-
duced method, is known to permit early identification of
systolic dysfunction even when left ventricular is still pre-
served. In this study, however, it was not used [12-14].
Assessing LV diastolic function in TI patients, the
mean LA volume and diameter were significantly higher
in TI with higher TRV. There was also a progressive in-
crease of the late filling velocity and a relative decrease
of the mitral inflow E/A ratio though statistically insig-
nificant. This suggests an increase in LV end diastolic
pressure, reflecting an alteration in diastolic property
and impairment of LV relaxation, most probably causedFigure 2 Association of TRV with LVEDD.by iron deposition which gradually, if not properly man-
aged, leads to restrictive cardiomyopathy [12,15,16]. The
left atrial diameter in Aessopos et al. [3] was significantly
larger in TI compared to control and the peak late trans-
mitral diastolic velocity was significantly higher in TI.
On the other hand the E/A ratio in Vaccari et al. and
Noori et al. studies were significantly lower in TI com-
pared to control group [10,11].
Congestive heart failure (CHF) in this study was en-
countered in 3(4.9%) patients. Yet, the rates of CHF in
Aessopos et al. [2] and Aessopos et al. [17] were 2.7%
and 5.4% respectively. In TI, the heart is primarily af-
fected by PHT, which is the leading cause of CHF due to
subsequent right ventricle dysfunction [18]. The current
study showed that there was a decrease in the value of
tricuspid annular plane systolic excursion in higher TRV
subgroup. However, it did not show a statistical signifi-
cant difference.
In the present study 8(13%) of cases had TRV ≥ 3.0 m/sec
which corresponds to doppler peak systolic tricuspid
gradient (PTG) greater than 30 mm Hg and 6(9%) hadFigure 4 Association of TRV with LA diameter.
Figure 5 Association of TRV with RV diameter. Figure 7 Association of TRV with PR.
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data the last value was considered to represent the actual
cases of PHT in this study relying on diagnostic conclusions
of PHT from a recent Italian study [19]. In Aessopos et al.
(59.1%) had PTG greater than 30 mmHg and (23%) had
PTG> 35 mmHg [17]. The observation that markers of
hemolysis are associated with pulmonary hypertension in
chronic hemolytic disorders suggests that there is a distinct
syndrome of hemolysis-associated pulmonary hypertension.
Following the release of hemoglobin into plasma, the
plasma hemoglobin can scavenge nitric oxide as well as
catalyze the formation of reactive oxygen and nitrogen spe-
cies, the processes that can lead to acute and chronic
pulmonary vasoconstriction [20]. With regard to the TI
clinical characteristics, a retrospective analysis showed that
splenectomised females with significant anemia, thrombo-
cytosis and elevated ferritin levels, were at greatest risk for
developing PHT [21,22].
This study, similar to above analysis, proved that TRV
was significantly higher in splenectomised cases, lower
hemoglobin, higher ferritin levels, and later onset of blood
transfusion. On the contrary, it concluded that higherFigure 6 Association of TRV with RA area.TRV was associated with male gender. Unsurprisingly,
despite of less regular blood transfusion among higher
TRV subgroup in the year before this study, relative higher
ferritin levels among them was found which was partly at-
tributed to lesser utilization of iron chelation in the same
subgroup, the increased risk of progressive ferritn accu-
mulation with advancing age and increased rate of gas-
rointerstinal iron absorption in TI [23,24].
A recent study demonstrated a significant correlation
between iron overload in the liver and pulmonary artery
systolic pressure independent of LV filling pressures
[25]. Though this study had made no data with regard to
iron overload in the liver, a significant association be-
tween higher ferritin levels and increase in pulmonary
artery systolic pressure and higher jet velocity of tricus-
pid regurgitation was found. The use of serum ferritin to
monitor iron overload is inexpensive and accessible. In
TI, serum ferritin assays may underestimate the actual
iron load and liver iron concentration (LIC) is more reli-
able, though invasive [26].
Managing TI patients with cardiac involvement and
PHT, regular transfusion and iron chelation therapy isFigure 8 Association of TRV with LVEF %.
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This suggests that TI patients may still be at risk for iron
related cardiac dysfunction through exposure to non-
transferrin bound iron [27,28]. However, only 25% of the
studied patients did receive regular blood transfusion,
and even among patients with cardiac manifestations
only few cases received iron chelation therapy. Sildenafil
has been successfully used to treat PHT. However, none
of the patients have had received the drug [29]. Hydro-
xycarbamide may be administered in TI patients in order
to minimize, or even obviate, the need for regular trans-
fusions and concomitant iron overload, and eventually
minimize the cardiac involvement. Again, only a few
cases have been receiving the drug, and with fair out-
come and compliance [30].
The main limitations of this study, which is, to my
best knowledge, the first attempt conducted in Iraq on
echocardiographic evaluation of TI, include reliance on
conventional echocardiography. Other diagnostic tools,
such as tissue doppler, speckled tracking echocardiog-
raphy, cardiac catheterization, and cardiac MRI, were
not accessible. The studied sample is relatively small to
generalize the outcomes, though it resulted in a correl-
ation between accumulative changes in the clinical char-
acteristics and echocardiographic parameters.
Conclusions
Conventional echocardiography for TI cases is a useful
tool for preliminary evaluation of cardiac status. It could
uncover many cardiac abnormalities that possibly com-
plicate TI. The abnormalities and the underlying patho-
physiology could be targeted in the future.
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